Prevalence of diabetes and hypertension based on self-reported morbidity survey, Brazil, 2006

Departamento de Medicina Social, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brasil.
Revista de saude publica (Impact Factor: 0.73). 11/2009; 43 Suppl 2:74-82.
Source: PubMed

ABSTRACT To estimate the prevalence of self-reported diabetes and hypertension and their absolute numbers in Brazil.
Data from 54,369 individuals aged > or = 18 years, interviewed by the Vigilância de Fatores de Risco e Proteção para Doenças Crônicas por Inquérito Telefônico (VIGITEL--Telephone-based Surveillance of Risk and Protective Factors for Chronic Diseases), conducted in 27 Brazilian state capitals in 2006, and who responded positively to questions about high blood pressure and diabetes, were analyzed. Percentages of self-reported hypertension and diabetes, estimated in the sample, were projected to the Brazilian population, according to age, sex and nutritional status, using the direct standardization method.
Prevalence of diabetes was 5.3% higher in women (6.0% vs. 4.4%), varying from 2.9% in Palmas (Northern Brazil) to 6.2% in São Paulo ( Southeastern Brazil). Prevalence of hypertension was 21.6% (21.3; 22.0) higher in women (24.4% vs. 18.4%), varying from 15.1% in Palmas to 24.9% in Recife (Northeastern Brazil). Prevalences increased with age and nutritional status. It was estimated that there were 6,317,621 adults who reported having diabetes and 25,690,145 adults who reported having hypertension in Brazil.
Prevalence of self-reported diabetes and hypertension are high in Brazil. Monitoring of these and other health conditions can be performed using strategies such as the VIGITEL, especially if followed by validation studies, aiming to generalize results.

Download full-text


Available from: Lenildo de Moura, Sep 25, 2015
18 Reads
  • Source
    • "Similarly, Plotnikoff et al. [20] identified that age was positively related to healthcare utilization in Canadian persons with both types of diabetes. In fact, ageing is frequently pointed out as an independent risk factor for development of several chronic diseases, including T2DM [1,3,8,21]. Additionally, the period of disease onset during the lifespan may be a determinant of the magnitude in healthcare expenditures, due to the co-morbidities associated to prolonged diabetes [22,23]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Determinants of public healthcare expenditures in type 2 diabetics are not well investigated in developing nations and, therefore, it is not clear if higher physical activity decreases healthcare costs. The purpose of this study was to analyze the relationship between physical activity and the expenditures in public healthcare on type 2 diabetes mellitus treatment. Cross-sectional study carried out in Brazil. A total of 121 type 2 diabetics attended to in two Basic Healthcare Units were evaluated. Public healthcare expenditures in the last year were estimated using a specific standard table. Also evaluated were: socio-demographic variables; chronological age; exogenous insulin use; smoking habits; fasting glucose test; diabetic neuropathy and anthropometric measures. Habitual physical activity was assessed by questionnaire. Age (r = 0.20; p = 0.023), body mass index (r = 0.33; p = 0.001) and waist-to-hip ratio (r = 0.20; p = 0.025) were positively related to expenditures on medication for the treatment of diseases other than diabetes. Insulin use was associated with increased expenditures. Higher physical activity was associated with lower expenditure, provided medication for treatment of diseases other than diabetes (OR = 0.19; p = 0.007) and medical consultations (OR = 0.26; p = 0.029). Type 2 diabetics with higher enrollment in physical activity presented consistently lower healthcare expenditures for the public healthcare system.
    BMC Public Health 05/2011; 11(1):275. DOI:10.1186/1471-2458-11-275 · 2.26 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This study aims to evaluate the effectiveness of the duodenojejunal bypass liner (DJBL) in the improvement of insulin resistance and reduction of cardiovascular risk among morbidly obese patients with type 2 diabetes mellitus, using the triglyceride/high-density lipoprotein (HDL) cholesterol ratio, percentage of weight loss, and glycemic control. We used the TG/HDL ratio with a cutoff value of 3.5 to identify patients with insulin resistance. The value of the initial ratio was compared with the ratio obtained 6 months after implantation to evaluate whether an improvement in insulin resistance occurred. We also evaluated the improvement of glycated hemoglobin levels and the weight loss resulted from the use of the device and correlated that with the improvement of the TG/HDL ratio. All patients implanted with the device presented a statistically significant reduction of the HbA1c levels, with most patients (70.3%) obtaining diabetes control with HbA1c levels lower than 7% at the end of the study. All patients also presented a significant weight reduction, with an average loss of 12.6% of their initial weight. We observed an important improvement in insulin resistance and metabolic syndrome, with a significant reduction of the TG/HDL ratio from 5.75 to 4.36 (p < 0.001) and 42.6% of the patients presenting a TG/HDL ratio lower than 3.5 at the end of the study. The DJBL, when used for a period of 6 months, is effective in the control of diabetes, weight loss, improvement of insulin resistance, and decrease of cardiovascular risk among morbidly obese patients with type 2 diabetes mellitus.
    Obesity Surgery 03/2011; 21(7):941-7. DOI:10.1007/s11695-011-0387-0 · 3.75 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to evaluate the effect of the duodenal-jejunal bypass liner (DJBL), a 60-cm, impermeable fluoropolymer liner anchored in the duodenum to create a duodenal-jejunal bypass, on metabolic parameters in obese subjects with type 2 diabetes. Twenty-two subjects (mean age, 46.2±10.5 years) with type 2 diabetes and a body mass index between 40 and 60 kg/m(2) (mean body mass index, 44.8±7.4 kg/m(2)) were enrolled in this 52-week, prospective, open-label clinical trial. Endoscopic device implantation was performed with the patient under general anesthesia, and the subjects were examined periodically during the next 52 weeks. Primary end points included changes in fasting blood glucose and insulin levels and changes in hemoglobin A1c (HbA1c). The DJBL was removed endoscopically at the end of the study. Thirteen subjects completed the 52-week study, and the mean duration of the implant period for all subjects was 41.9±3.2 weeks. Reasons for early removal of the device included device migration (n=3), gastrointestinal bleeding (n=1), abdominal pain (n=2), principal investigator request (n=2), and discovery of an unrelated malignancy (n=1). Using last observation carried forward, statistically significant reductions in fasting blood glucose (-30.3±10.2 mg/dL), fasting insulin (-7.3±2.6 μU/mL), and HbA1c (-2.1±0.3%) were observed. At the end of the study, 16 of the 22 subjects had an HbA1c<7% compared with only one of 22 at baseline. Upper abdominal pain (n=11), back pain (n=5), nausea (n=7), and vomiting (n=7) were the most common device-related adverse events. The DJBL improves glycemic status in obese subjects with diabetes and therefore represents a nonsurgical, reversible alternative to bariatric surgery.
    Diabetes Technology &amp Therapeutics 09/2011; 14(2):183-9. DOI:10.1089/dia.2011.0152 · 2.11 Impact Factor
Show more